KAHLERMID L® (Lenalidomide) has granted the Marketing Authorization

LEKLI Announces that the National Agency for Medicines and Medical Devices, has granted the Marketing Authorization for Lenalidomide (KAHLERMID L®), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition and direct antineoplastic effects.

It has been extensively studied for the treatment of multiple myeloma and myelodysplastic syndrome as well as lymphoproliferative disorders including chronic lymphocyctic leukemia (CLL) and non-Hodgkin lymphoma.